Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials

American Journal of Geriatric Psychiatry

Volumn 14, Issue 1, 2006, Pages 62-70

  Micca, Joseph L ^a   Hoffmann, Vicki Poole ^b   Lipkovich, Ilya ^b   Ahl, Jonna ^b   Baker, Robert W ^b   Hardy, Thomas A ^b  

^a Beverly Healthcare Northside   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Dementia; Diabetes risk; Elderly; Olazapine; Treatment emergent diabetes

Indexed keywords

ANTIDIABETIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE;

AGED; AGING; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; WEIGHT GAIN;

EID: 31044445407     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000192477.05061.96     Document Type: Article

References (32)

1. Dixon L, Weiden P, Delahanty J, et al: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26:903-912
2. Egede LE, Zheng D, Simpson K: Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25:464-470
3. Cassidy F, Ahearn E, Carroll BJ: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156:1417-1420
4. American Diabetes Association: Screening for type 2 diabetes. Clinical practice recommendations. Diabetes Care 2003; 26:S21-S24
5. Dynes JB: Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Sys 1969; 30:341-344
6. Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 1:495
7. Brown S, Inskip H, Barraclough B: Causes of excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217
8. Ryan MCM, Thakore JH: Physical consequences of schizophrenia and its treatment. The metabolic syndrome. Life Sci 2002; 71:239-257
9. Buse JB, Cavazzoni P, Hornbuckle K, et al: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56:164-170
10. Sernyak MJ, Leslie DL, Alarcon RD, et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566
11. Koro CE, Fedder DO, L'Italien GJ, et al: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325:243
12. American Diabetes Association: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27:596-601
13. Alexopoulos GS, Streim J, Carpenter D, et al: Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Supplement 2:5-99.
14. Street JS, Clark WS, Gannon KS, et al: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57:968-976
15. DeDeyn PP, Carrasco MM, Deberdt W, et al: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19:115-126
16. Deberdt WG, Dysken MW, Rappaport SA, et al: Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Arch Gen Psychiatry 2005; 13:722-730
17. Kennedy JS, Bymaster FP, Schuh L, et al: A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Pyschiatry 2001; 16:S33-S61
18. Feldman PD, Hay LK, Deberdt W, et al: Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004; 5:38-46
19. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
20. Folstein MF, Folstein SE, McHugh PR: Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
21. Etminan M, Streiner DL, Rochon PA: Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003; 23:1411-1415
22. Barak Y, Shamir E, Zemishlani H, et al: Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:1199-1202
23. Barak Y, Shamir E, Mirecki I, et al: Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol 2004; 7:165-169
24. Barak Y, Aizenberg D: Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drugs Aging 2003; 20:893-896
25. Meyer JM: A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425-433
26. White H, Pieper C, Schmader K: The association of weight changes in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998; 46:1223-1227
27. White H, Pieper C, Schmader K, et al: Weight change in Alzheimer's disease. J Am Geriatr Soc 1996; 44:265-272
28. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive synthesis. Am J Psychiatry 1999; 156:1686-1696
29. Kenny SJ, Aubert RE, Geiss LS: Prevalence and incidence of non-insulin-dependent diabetes, in Diabetes in America, 2nd ed. Edited by Harris M, Coowie CC, Reiber G, et al. Washington, DC, U.S. Govt. Printing Office 1995, pp 47-68
30. Kinon BJ, Stauffer VL, McGuire HC, et al: The effects of antipsychotic treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc 2003; 4:189-194
31. Street JS, Clark WS, Kadam DL, et al: Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001; 16(suppl 1):S62-70
32. Kennedy J, Deberdt W, Siegal A, et al: Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry 2005; 20:1020-1027